Ikena Oncology, Inc. - IKNA STOCK NEWS

Ikena Oncology announced that the U.S. FDA has accepted its Investigational New Drug (IND) application for IK-930, a TEAD inhibitor targeting genetic alterations in the Hippo pathway. This marks a crucial step towards their first-in-human phase 1 clinical trial, set to begin in early 2022, focusing on patients with solid tumors like NF2-deficient malignant mesothelioma. Ikena aims to evaluate the effectiveness of IK-930, both as a standalone treatment and in combination with other therapies, addressing significant unmet needs in oncology.

Ikena Oncology presented new data at the AACR-NCI-EORTC International Conference, highlighting their lead TEAD inhibitor, IK-930. The findings suggest potential for IK-930 in treating NF2-deficient mesothelioma and other cancer types with Hippo pathway mutations. The data also indicate promising combinations of IK-930 with EGFR and MEK inhibitors. Presenters Jeffrey Ecsedy and Marta Sanchez-Martin emphasized the importance of patient selection and a biomarker-driven approach in clinical development. Ikena aims to leverage these insights for effective cancer therapies.

Ikena Oncology (Nasdaq: IKNA) announced the presentation of three abstracts focused on their Aryl Hydrocarbon Receptor (AHR) antagonist program at the SITC 2021 Annual Meeting, taking place from November 10-14, 2021. The highlighted inhibitor, IK-175, is an oral AHR antagonist currently in a Phase 1 clinical trial designed to enhance immunity against cancer. The abstracts will cover various studies, including the efficacy of IK-175 in treating patients with advanced solid tumors.

Ikena Oncology (Nasdaq: IKNA) announced participation in the virtual Morgan Stanley 19th Annual Global Healthcare Conference from September 9-15, 2021, and the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. Management will engage in a fireside chat on September 10, 2021, at 10:15 am EST during the Morgan Stanley conference. Webcasts are accessible for replay through the company's website, available for 90 days post-event. Ikena focuses on developing novel cancer therapies targeting key signaling pathways.

Ikena Oncology (Nasdaq: IKNA) reported its Q2 financial results for 2021, showing a net loss of $12.7 million, up from $5.0 million in Q2 2020. R&D expenses rose to $11.4 million, driven by ongoing IND-enabling studies. The company holds $264 million in cash, sufficient to fund operations through 2023. Key pipeline developments include advancing the IK-175 clinical trial in bladder cancer and preparing for IK-930 IND submission by year-end. Upcoming presentations at scientific conferences are expected to further elaborate on the efficacy of their therapies.

Ikena Oncology (Nasdaq: IKNA) will participate in the William Blair Biotech Focus Conference on July 15, 2021. CEO Dr. Mark Manfredi will engage in a panel discussion focused on next-generation approaches to targeted oncology. The panel is scheduled for 9:00 – 9:45 a.m. ET and will be available via a live webcast. Ikena is known for developing therapies targeting cancer's key signaling pathways and has ongoing programs including IK-930 and IK-175. The webcast will be archived for 30 days after the event.

Ikena Oncology (Nasdaq: IKNA) will participate in a fireside chat at the 2021 Jefferies Virtual Healthcare Conference on June 2, 2021, at 2:00 p.m. ET. The event will be available through a live webcast on the company's website, with an archive accessible for 30 days post-event. Ikena is focused on cancer therapies targeting key signaling pathways and has five active programs, including collaborations with Bristol-Myers Squibb for IK-175 and IK-412. For more details, visit www.ikenaoncology.com.

Ikena Oncology (Nasdaq: IKNA) reported its financial results for Q1 2021, marking significant milestones including a successful IPO that raised $143.8 million. The company is focused on developing targeted cancer therapies and has made progress with its clinical pipeline. IND-enabling studies for lead program IK-930 are ongoing, with a submission expected in H2 2021. As of March 31, 2021, Ikena had $281 million in cash, with a net loss of $9.7 million for the quarter, driven by increased R&D expenses.

Ikena Oncology, Inc. (Nasdaq: IKNA) has appointed Maria Koehler, M.D., Ph.D., to its Board of Directors. Dr. Koehler has over 20 years of experience in oncology drug development, previously holding senior positions at Pfizer and leading the development of Ibrance®. Mark Manfredi, CEO of Ikena, expressed enthusiasm for her addition during the company's growth phase, especially as it advances its lead candidate IK-930 into clinical development. Dr. Koehler aims to leverage her extensive experience to drive Ikena's innovative drug candidates forward.